Short-term entecavir therapy of chronic severe hepatitis B

Hepatobiliary and Pancreatic Diseases International

Volumn 8, Issue 3, 2009, Pages 261-266

  Chen, Jun ^a   Han, Jian Hua ^a   Liu, Chun ^a   Yu, Ren He ^b   Li, Fa Zhao ^a   Li, Qun Fang ^a   Gong, Guo Zhong ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Chronic severe hepatitis; Entecavir; Mortality

Indexed keywords

DNA; ENTECAVIR;

ADOLESCENT; ADULT; AGED; ARTICLE; CHRONIC HEPATITIS; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; END STAGE LIVER DISEASE; FEMALE; HEPATITIS B; HUMAN; LIVER DISEASE; LIVER FAILURE; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; SCORING SYSTEM; SURVIVAL RATE; VIRUS REPLICATION;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; DISEASE PROGRESSION; DNA, VIRAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; GUANINE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LIVER; LIVER FAILURE; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; VIRUS REPLICATION; YOUNG ADULT;

EID: 67549132276     PISSN: 14993872     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Poison J, Lee WM; American Association for the Study of Liver Disease. AASLD position paper: the management of acute liver failure. Hepatology 2005;41:1179-1197.
2. Mast EE, Alter MJ, Margolis HS. Strategies to prevent and control hepatitis B and C virus infections: a global perspective. Vaccine 1999;17:1730-1733. (Pubitemid 29138908)
3. McQuillan GM, Coleman PJ, Kruszon-Moran D, Moyer LA, Lambert SB, Margolis HS. Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994. Am J Public Health 1999;89:14-18.
4. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-1531. (Pubitemid 39315319)
5. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005;352:2673-2681. (Pubitemid 41007822)
6. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354:1001-1010. (Pubitemid 43357804)
7. Gaeta GB, Stornaiuolo G. Therapy of chronic hepatitis B: focus on telbivudine. Dig Liver Dis 2007;39:S372-378. (Pubitemid 350182973)
8. Bonino F, Brunetto MR. Hepatitis B virus heterogeneity, one of many factors influencing the severity of hepatitis B. J Hepatol 1993;18:5-8. (Pubitemid 23166345)
9. Yao FY, Bass NM. Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection. J Hepatol 2000;33:301-307. (Pubitemid 30485234)
10. Tillmann HL, Hadern J, Leifeld L, Zachou K, Canbay A, Eisenbach C, et al. Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience. J Viral Hepat 2006;13:256-263.
11. Dai CY, Yu ML, Hsieh MY, Lee LP, Hou NJ, Huang JF, et al. Early response to lamivudine therapy in clinically non-cirrhotic chronic hepatitis B patients with decompensation. Liver Int 2007;27:1364-1370.
12. Ono SK, Kato N, Shiratori Y, Kato J, Goto T, Schinazi RF, et al. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J Clin Invest 2001;107:449-455. (Pubitemid 32167991)
13. Board of liver diseases, infectious diseases and parasitic diseases of Chinese Medical Association, National viral hepatitis control programme. Zhonghua Gan Zang Bing Za Zhi 2000;6:324-329.
14. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33:464-470. (Pubitemid 32119037)
15. Freeman RB Jr, Wiesner RH, Roberts JP, McDiarmid S, Dykstra DM, Merion RM. Improving liver allocation: MELD and PELD. Am J Transplant 2004;4:114-131. (Pubitemid 38859000)
16. Botta F, Giannini E, Romagnoli P, Fasoli A, Malfatti F, Chiarbonello B, et al. MELD scoring system is useful for predicting prognosis in patients with liver cirrhosis and is correlated with residual liver function: a European study. Gut 2003;52:134-139. (Pubitemid 36020780)
17. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000;31:864-871.
18. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45:507-539. (Pubitemid 46374607)
19. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73. (Pubitemid 43042691)
20. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006;130:678-686. (Pubitemid 43374518)
21. Xu JH, Yu YY, Si CW, Zeng Z, Wang QH, Luo DD, et al. Promoting hepatic growth factor in the treatment of heavy type hepatitis and severe chronic hepatitis: a multicenter clinical study. Hepatobiliary Pancreat Dis Int 2004;3:381-385. (Pubitemid 39173070)
22. Xing T, Li L, Cao H, Huang J. Altered immune function of monocytes in different stages of patients with acute on chronic liver failure. Clin Exp Immunol 2007;147:184-188. (Pubitemid 44915570)